Logo image of PBH

PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Price, Forecast & Analysis

USA - New York Stock Exchange - NYSE:PBH - US74112D1019 - Common Stock

64.17 USD
+0.21 (+0.33%)
Last: 1/9/2026, 8:16:00 PM
65.9999 USD
+1.83 (+2.85%)
After Hours: 1/9/2026, 8:16:00 PM

PBH Key Statistics, Chart & Performance

Key Statistics
Market Cap3.09B
Revenue(TTM)1.11B
Net Income(TTM)200.84M
Shares48.08M
Float47.46M
52 Week High90.04
52 Week Low57.25
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)4.56
PE14.07
Fwd PE13.11
Earnings (Next)02-04 2026-02-04/bmo
IPO2005-02-10
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


PBH short term performance overview.The bars show the price performance of PBH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 -10 -15

PBH long term performance overview.The bars show the price performance of PBH in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -5 -10

The current stock price of PBH is 64.17 USD. In the past month the price increased by 4.58%. In the past year, price decreased by -13.28%.

PRESTIGE CONSUMER HEALTHCARE / PBH Daily stock chart

PBH Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 48.37 1.01T
JNJ JOHNSON & JOHNSON 19.69 492.44B
MRK MERCK & CO. INC. 12.55 274.34B
PFE PFIZER INC 7.96 144.87B
BMY BRISTOL-MYERS SQUIBB CO 8.52 113.72B
ZTS ZOETIS INC 20.06 56.04B
RPRX ROYALTY PHARMA PLC- CL A 9.77 23.19B
VTRS VIATRIS INC 5.48 14.70B
ELAN ELANCO ANIMAL HEALTH INC 24.45 11.66B
AXSM AXSOME THERAPEUTICS INC N/A 8.54B
BLTE BELITE BIO INC - ADR N/A 5.53B
CRNX CRINETICS PHARMACEUTICALS IN N/A 5.05B

About PBH

Company Profile

PBH logo image Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. The company is headquartered in Tarrytown, New York and currently employs 600 full-time employees. The company went IPO on 2005-02-10. The firm is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.

Company Info

PRESTIGE CONSUMER HEALTHCARE

660 White Plains Rd.

Tarrytown NEW YORK 10591 US

CEO: Ronald M. Lombardi

Employees: 600

PBH Company Website

PBH Investor Relations

Phone: 19145246800

PRESTIGE CONSUMER HEALTHCARE / PBH FAQ

What does PRESTIGE CONSUMER HEALTHCARE do?

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. The company is headquartered in Tarrytown, New York and currently employs 600 full-time employees. The company went IPO on 2005-02-10. The firm is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.


Can you provide the latest stock price for PRESTIGE CONSUMER HEALTHCARE?

The current stock price of PBH is 64.17 USD. The price increased by 0.33% in the last trading session.


Does PBH stock pay dividends?

PBH does not pay a dividend.


How is the ChartMill rating for PRESTIGE CONSUMER HEALTHCARE?

PBH has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Can you provide the PE ratio for PBH stock?

The PE ratio for PRESTIGE CONSUMER HEALTHCARE (PBH) is 14.07. This is based on the reported non-GAAP earnings per share of 4.56 and the current share price of 64.17 USD.


Can you provide the upcoming dividend date for PRESTIGE CONSUMER HEALTHCARE?

The next ex-dividend date for PRESTIGE CONSUMER HEALTHCARE (PBH) is December 30, 2021.


Should I buy PBH stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PBH.


PBH Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to PBH. When comparing the yearly performance of all stocks, PBH is a bad performer in the overall market: 74.67% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

PBH Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to PBH. PBH gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PBH Financial Highlights

Over the last trailing twelve months PBH reported a non-GAAP Earnings per Share(EPS) of 4.56. The EPS increased by 13.15% compared to the year before.


Industry RankSector Rank
PM (TTM) 18.09%
ROA 5.83%
ROE 11%
Debt/Equity 0.55
Chartmill High Growth Momentum
EPS Q2Q%-1.83%
Sales Q2Q%-3.41%
EPS 1Y (TTM)13.15%
Revenue 1Y (TTM)-0.02%

PBH Forecast & Estimates

10 analysts have analysed PBH and the average price target is 79.05 USD. This implies a price increase of 23.19% is expected in the next year compared to the current price of 64.17.

For the next year, analysts expect an EPS growth of 1.64% and a revenue growth -2.01% for PBH


Analysts
Analysts84
Price Target79.05 (23.19%)
EPS Next Y1.64%
Revenue Next Year-2.01%

PBH Ownership

Ownership
Inst Owners108.83%
Ins Owners1.31%
Short Float %4.5%
Short Ratio4.94